Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hisamitsu Pharmaceutical Co's average Book Value per Share Growth Rate was 9.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 7.90% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 6.10% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Hisamitsu Pharmaceutical Co was 14.20% per year. The lowest was 1.90% per year. And the median was 7.50% per year.
Hisamitsu Pharmaceutical Co (FSE:4530) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Hisamitsu Pharmaceutical Co 3-Year Book Growth Rate Related Terms
FSE:4530 vs AMPH, ESPR, NIKA: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate falls into.
Hisamitsu Pharmaceutical Co 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 7.90% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 3-Year Book Growth Rate of 7.90% as of Feb. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 7.50. Over the past decade, Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate has ranged from 1.90 to 14.20.
Is Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate too high?
Hisamitsu Pharmaceutical Co's current 3-Year Book Growth Rate of 7.90% is near median its 10-year median of 7.50. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 14.20. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Hisamitsu Pharmaceutical Co's value of 7.90% is 71.7% above this industry median. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's 3-Year Book Growth Rate of 7.90% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year Book Growth Rate is 4.60. Hisamitsu Pharmaceutical Co's value of 7.90% is 71.7% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own 3-Year Book Growth Rate has ranged from 1.90 to 14.20 over the past decade. While the company's 10-year median is 7.50 vs. the industry median of 4.60, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current 3-Year Book Growth Rate of 7.90% is 71.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current 3-Year Book Growth Rate is 7.90%, which is near median its own 10-year median of 7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 3-Year Book Growth Rate of 7.90%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 3-Year Book Growth Rate is 7.90%, which is near median its 10-year median of 7.50 and 71.7% above the Drug Manufacturers industry median of 4.60. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 3-Year Book Growth Rate is 7.90% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
3-Year Book Growth Rate: 7.90% (near median its 10-year median of 7.50)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 71.7% above the Drug Manufacturers median
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
